AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor International Website | For Healthcare Professionals Outside the U.S. | US Residents
AFINITOR® Patient Profiles
When disease progresses after initial VEGF**-targeted therapy, it may be time for AFINITOR (everolimus) tablets, an oral mTOR inhibitor
Once-daily, oral AFINITOR is the first and only therapy with Phase III evidence after a VEGF-targeted therapy.
AFINITOR received the highest Category of recommendation from the NCCN, which endorses it as the only Category 1 treatment following a first-line VEGF TKI (eg, sunitinib or sorafenib).
The people depicted in the photos above are models and are being used for illustrative purposes only. The information presented is based on individual patient cases. Clinical response to AFINITOR therapy may vary by patient.
*MSKCC: Memorial Sloan-Kettering Cancer Center
**VEGF: vascular endothelial growth factor
